Iterum Therapeutics plc
General ticker "ITRM" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $30.2M (TTM average)
Iterum Therapeutics plc does not follow the US Stock Market performance with the rate: -18.5%.
Estimated limits based on current volatility of 5.7%: low 0.42$, high 0.47$
Factors to consider:
- Total employees count: 9 as of 2024
- Top business risk factors: Dependency on sulopenem program, Cybersecurity threats, Regulatory and compliance, Labor/talent shortage/retention, Commercialization challenges
- Current price 55.1% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.98$, 2.81$]
- 2025-12-31 to 2026-12-31 estimated range: [0.65$, 1.96$]
Financial Metrics affecting the ITRM estimates:
- Positive: with PPE of -1.5 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -75.59 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 51.41 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term ITRM quotes
Long-term ITRM plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $30.38MM | $47.47MM | $18.70MM |
| Operating Income | $-30.38MM | $-47.47MM | $-18.70MM |
| Non-Operating Income | $-13.75MM | $9.71MM | $-5.84MM |
| Interest Expense | $2.36MM | $0.00MM | $0.00MM |
| R&D Expense | $15.82MM | $38.24MM | $10.46MM |
| Income(Loss) | $-44.13MM | $-37.76MM | $-24.53MM |
| Taxes | $0.30MM | $0.61MM | $0.24MM |
| Profit(Loss)* | $-44.43MM | $-38.37MM | $-24.77MM |
| Stockholders Equity | $28.00MM | $-6.40MM | $-4.08MM |
| Assets | $66.83MM | $26.26MM | $44.59MM |
| Operating Cash Flow | $-18.47MM | $-39.33MM | $-26.77MM |
| Capital expenditure | $0.06MM | $0.01MM | $0.00MM |
| Investing Cash Flow | $13.96MM | $23.34MM | $18.21MM |
| Financing Cash Flow | $-1.82MM | $1.03MM | $26.69MM |
| Earnings Per Share** | $-3.63 | $-2.96 | $-1.26 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.